Drug Profile
Atorvastatin/dalcetrapib
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche
- Class Antihyperlipidaemics; Fatty acids; Heptanoic acids; Pyrroles; Small molecules; Sulfhydryl compounds; Thioesters
- Mechanism of Action Cholesterol ester transfer protein inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lipid metabolism disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Lipid-metabolism-disorders(In volunteers) in New Zealand
- 19 Sep 2011 Roche completes a phase I trial in Healthy volunteers in New Zealand (NCT01363999)